Xenon Pharmaceuticals Inc. 4
4 · Xenon Pharmaceuticals Inc. · Filed Mar 14, 2017
Insider Transaction Report
Form 4
GOLDBERG Y. PAUL
VP of Clinical Development
Transactions
- Award
Stock Option (Right to Buy)
2017-03-13+27,500→ 27,500 totalExercise: $8.40Exp: 2027-03-12→ Common Shares (27,500 underlying)
Footnotes (1)
- [F1]Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.